Page last updated: 2024-12-06
ketazolam
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ketazolam: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 33746 |
CHEMBL ID | 2104356 |
CHEBI ID | 135556 |
SCHEMBL ID | 157329 |
MeSH ID | M0042539 |
Synonyms (66)
Synonym |
---|
4h-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- |
anxon |
loftran |
anseren |
sedotime |
u-28,774 |
nsc338158 |
ketazolam |
unakalm |
27223-35-4 |
ansieten |
4h-[1,2-d][1,4]benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- |
nsc-338158 |
11-chloro-8,8-dimethyl-12b-phenyl-4h-[1,3]-oxazino[3,2-d]-[1,4]benzodiazepine-4,7(6h)dione |
u 28774 |
4h-[1,2-d]-[1,4]benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl- |
11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione |
nsc 338158 |
ketazolamum [inn-latin] |
11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)dione |
4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione, 8,12b-dihydro-11-chloro-2,8-dimethyl-12b-phenyl- |
einecs 248-346-3 |
4h-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl- |
ketazolam (usan/inn) |
D04650 |
DB01587 |
CHEBI:135556 |
11-chloro-2,8-dimethyl-12b-phenyl-6h-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione |
CHEMBL2104356 |
u-28774 |
4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- |
ketazolamum |
ketazolam [usan:inn:ban] |
unii-92a214md7y |
92a214md7y , |
ketazolam [mi] |
ketazolam [who-dd] |
ketazolam [inn] |
ketazolam [mart.] |
(+/-)-ketazolam |
ketazolam [usan] |
103794-94-1 |
SCHEMBL157329 |
11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)-oxazino(3,2-d)[1,4]benzodiazepine-4,7(6h)-dione |
4h-(1,3)-oxazino(3,2-d)-(1,4)benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl- |
PWAJCNITSBZRBL-UHFFFAOYSA-N |
11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)-oxazino(3,2-d)-(1,4)benzodiazepine-4,7(6h)dione |
11-chloro-2,8-dimethyl-12b-phenyl-8,12b-dihydro-4h-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6h)-dione |
14-chloro-4,10-dimethyl-2-phenyl-3-oxa-7,10-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(11),4,12,14-tetraene-6,9-dione |
HY-A0242 |
CS-6737 |
ketazolam; 11-chloro-2,8-dimethyl-12b-phenyl-6h-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-quinone; 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)dione; 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h |
Q2397253 |
DTXSID20865350 |
(+)-ketazolam |
9ZBH5G9835 , |
4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-, (-)- |
424J5HGB8E , |
106939-00-8 |
106938-99-2 |
4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-, (+)- |
ketazolam, (+)- |
ketazolam, (-)- |
(-)-ketazolam |
unii-424j5hgb8e |
unii-9zbh5g9835 |
Research Excerpts
Overview
Ketazolam is a relatively safe and clinically effective antispasticity agent (especially for patients with multiple sclerosis)
Excerpt | Reference | Relevance |
---|---|---|
"Ketazolam is a relatively safe and clinically effective antispasticity agent (especially for patients with multiple sclerosis)." | ( Ketazolam treatment for spasticity: double-blind study of a new drug. Basmajian, JV; Russell, D; Shankardass, K; Yucel, V, 1984) | 2.43 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
"Recently, it has been argued that benzodiazepines may not be safe or efficacious beyond 3 months continuous dosage." | ( Comparison of the therapeutic effect, tolerance and safety of ketazolam and diazepam administered for six months to out-patients with chronic anxiety neurosis. Fabre, LF; McLendon, DM; Stephens, AG, 1981) | 0.5 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
benzodiazepine | A group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (21)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 20 (95.24) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (4.76) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 56.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.02) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 14 (60.87%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (39.13%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |